🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 18 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
29/08/2022 24,55 25,21 24,09 24,67 -1,44% 4,54% 498.700
26/08/2022 26,66 26,66 24,69 25,03 -4,65% 7,39% 573.100
25/08/2022 26,07 26,25 25,41 26,25 +2,86% 3,22% 431.600
24/08/2022 25,88 26,99 25,19 25,52 -1,85% 6,96% 733.600
23/08/2022 25,58 26,29 24,97 26,00 +2,85% 5,16% 655.800
22/08/2022 25,52 26,22 24,86 25,28 -2,51% 5,33% 374.200
19/08/2022 25,02 26,12 24,76 25,93 +2,05% 5,44% 929.500
18/08/2022 26,28 26,28 25,35 25,41 -3,75% 3,54% 595.300
17/08/2022 26,94 27,42 26,36 26,40 -3,86% 3,92% 381.300
16/08/2022 27,87 28,47 27,22 27,46 -1,93% 4,49% 634.500
15/08/2022 27,18 28,44 26,77 28,00 +2,94% 6,14% 527.300
12/08/2022 26,27 27,94 25,88 27,20 +5,10% 7,84% 982.500
11/08/2022 27,02 27,59 25,57 25,88 -4,15% 7,46% 792.600
10/08/2022 26,13 27,55 25,33 27,00 +7,02% 8,50% 943.500
09/08/2022 26,31 26,45 24,45 25,23 -7,75% 7,60% 947.900
08/08/2022 27,32 27,79 26,42 27,35 +0,07% 5,01% 826.600
05/08/2022 26,22 27,57 25,57 27,33 +1,79% 7,63% 685.700
04/08/2022 24,83 27,43 24,83 26,85 +1,90% 10,47% 944.700
03/08/2022 25,94 27,48 25,93 26,35 +3,99% 5,96% 551.700
02/08/2022 24,46 25,90 24,46 25,34 +1,89% 5,89% 495.800
01/08/2022 26,20 26,53 24,53 24,87 -6,47% 7,63% 650.300
29/07/2022 26,66 26,68 26,01 26,59 -1,70% 2,53% 434.400
28/07/2022 27,45 27,45 25,96 27,05 -0,07% 5,43% 374.500
27/07/2022 26,71 27,11 25,99 27,07 +2,38% 4,19% 469.800
26/07/2022 25,91 27,04 25,49 26,44 +0,95% 5,98% 522.400
25/07/2022 26,73 26,73 25,79 26,19 -2,42% 3,52% 470.700
22/07/2022 28,39 28,88 26,65 26,84 -6,25% 7,85% 699.500
21/07/2022 29,08 29,46 28,51 28,63 -1,04% 3,27% 535.900
20/07/2022 28,80 29,86 28,40 28,93 +0,87% 5,05% 533.600
19/07/2022 28,22 28,98 27,61 28,68 +3,39% 4,85% 721.000